Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abatacept

Bristol Myers Squibb logo

Opdivo boosts survival in head and neck cancer by 30%

Pivotal trial of BMS’ PD-1 inhibitor shows "significant benefit" in overall survival

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo gets two new indications in Europe

Receives green light as lung and kidney cancer immunotherapy

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

Bristol Myers Squibb logo

Opdivo edges closer to first haematological cancer indication

EMA begins review of BMS' classic Hodgkin’s lymphoma inhibitor treatment

- PMLiVE

BMS appoints Peter Arduini to board of directors

He brings experience from Integra LifeSciences and Baxter Healthcare

Roche - Basel

Roche boosts cancer portfolio with $1bn Blueprint deal

Collaboration will focus on the development of its ‘immunokinases’ immuno-oncology treatment

- PMLiVE

Focus on multiple myeloma treatment: Witnessing a transformation

Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

Blue Latitude Health

AstraZeneca AZ global R&D corporate HQ

AZ’s tremelimumab fails mesothelioma trial

FDA-designated breakthrough therapy did not demonstrate increase in overall survival

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

Baxalta makes $1.7bn play for slice of CAR-T market

Three-year alliance with Precision BioSciences to expand immuno-oncology portfolio

Free Thinking: From promise to practice: immuno-oncology in action

Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically...

Research Partnership

EU flag

CHMP backs orphan drugs Uptravi and Coagadex

EMA advisors set Actelion and Bio Products therapies on path to European approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links